Pfizer to market Biohaven’s migraine drug outside of the United States

The strategic commercialization partnership will see Biohaven continue marketing the drug in the U.S.

Earlier in the week, pharmaceutical giant Pfizer announced it had entered into a strategic commercialization arrangement with Biohaven Pharmaceuticals to market the migraine drug rimegepant outside of the U.S. once approval is granted. According to the statement, the drug which is sold as Nurtec® ODT in the U.S. is used to treat ‘migraine attacks with or without aura and for the preventive treatment of episodic migraine in adults.’ The drug is currently under review by the European Medicines Agency and a few other regulatory authorities outside of the U.S. “We believe this collaboration, which brings together the winning combination of Biohaven’s Neuroscience R&D with Pfizer’s industry-leading expertise and large global footprint will help accelerate access to rimegepant for patients around the world,” said Vlad Coric MD, CEO of Biohaven.

Per the deal’s terms, Biohaven still remains primarily responsible for any further clinical development for the drug, while the duo would partner to secure regulatory approvals. Biohaven will continue commercializing Nurtec ODT on its own in the U.S, with Pfizer assuming responsibility for commercializing the drug abroad once approvals are granted. "We are excited to join forces with Biohaven in the fight against migraine and help those patients impacted by this debilitating neurological disease,” said Nick Lagunowich, Global President, Pfizer Internal Medicine. In addition, Pfizer would also gain rights ‘outside of the U.S. to zavegepant, a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, currently being studied in an intranasal delivery and a soft-gel formulation in Phase 3 clinical trials for migraine indications.’